Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sex differences in nevirapine rash
Autore:
Bersoff-Matcha, SJ; Miller, WC; Aberg, JA; van der Horst, C; Hamrick, HJ; Powderly, WG; Mundy, LM;
Indirizzi:
Washington Univ, Sch Med, St Louis, MO 63141 USA Washington Univ St LouisMO USA 63141 iv, Sch Med, St Louis, MO 63141 USA Univ N Carolina, Chapel Hill, NC USA Univ N Carolina Chapel Hill NC USAUniv N Carolina, Chapel Hill, NC USA Univ Calif San Francisco, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA
Titolo Testata:
CLINICAL INFECTIOUS DISEASES
fascicolo: 1, volume: 32, anno: 2001,
pagine: 124 - 129
SICI:
1058-4838(20010101)32:1<124:SDINR>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIV-INFECTED PATIENTS; CUTANEOUS REACTIONS; CONTROLLED TRIAL; DRUG-REACTIONS; DOUBLE-BLIND; ZIDOVUDINE; PHARMACOKINETICS; DIDANOSINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Mundy, LM Washington Univ, Sch Med, 660 S Euclid,Campus Box 8051, St Louis, MO 63141USA Washington Univ 660 S Euclid,Campus Box 8051 St Louis MO USA 63141
Citazione:
S.J. Bersoff-Matcha et al., "Sex differences in nevirapine rash", CLIN INF D, 32(1), 2001, pp. 124-129

Abstract

Nevirapine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) thathas the most common treatment limiting side effect of rash. Severe rash has been observed in 3% of patients taking nevirapine in clinical trials, 85%of whom were men. In a multicenter, retrospective cohort study of all patients who received nevirapine over a 5-year period, severe rash was noted in9 of 95 women and 3 of 263 men (risk ratio [RR], 8.31; 95% confidence interval [CI], 2.3-30.0; P=.005). Women were more likely to discontinue nevirapine therapy because of rash (RR, 4.5; 95% CI, 1.9-10.5; P=.0005). After adjusting for age and baseline CD4 cell count in multivariate analysis, women had a 7-fold increase in risk for severe rash and were 3.5 times more likely to discontinue nevirapine therapy. In women of reproductive age for whom contraception may occur, nevirapine remains the NNRTI of choice. Recognition of sex differences in this severe adverse event will be important in prescribing nevirapine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 23:35:21